Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 9Unknown 6Active not recruiting 4Recruiting 3Terminated 2Withdrawn 1Enrolling by invitation 1

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Syndrome 1Stevens-Johnson Syndrome 1Pemphigoid, Benign Mucous Membrane 1

Interventions

Radiotherapy 91pembrolizumab 88Cyclophosphamide 84Gemcitabine 70Cisplatin 70Magnetic Resonance Spectroscopy 65Carboplatin 60Radiosurgery 55Paclitaxel 55Nivolumab 48Dexamethasone 45Bevacizumab 42Biopsy 41Fluorouracil 39durvalumab 37Surveys and Questionnaires 36Docetaxel 36fludarabine 35Doxorubicin 35Radiation 33Oxaliplatin 33Capecitabine 33Rituximab 32fludarabine phosphate 31Leucovorin 31Cytarabine 30Melphalan 29Etoposide 28Pemetrexed 27Irinotecan 27

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × OTHER × Infliximab × Clear all
NCT02126020 2017-04-07

Topical Infliximab in Autoimmune Eyes With Keratoprosthesis

Massachusetts Eye and Ear Infirmary

Phase 1/2 Withdrawn

Pemphigoid, Benign Mucous Membrane, Stevens-Johnson Syndrome, Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡